Cipla open to collaborate with Eli Lilly to market its obesity drugs in India: CEO
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-05-11 06:00 GMT | Update On 2024-05-11 06:00 GMT
Bengaluru: The CEO of Cipla on friday expressed openness to collaborate with U.S. pharmaceutical company Eli Lilly for the marketing of their highly successful obesity treatment medications in India.'
Absolutely and always open...we value our partnership with Lilly tremendously and I think the two companies are culturally aligned," Cipla's Global CEO Umang Vohra said in response to a Reuters query.
Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. They belong to a therapy area of GLP-1 receptor agonists, developed to control blood sugar in patients with type 2 diabetes, but have gained popularity for their role in weight loss.
Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.
Lilly, in February, told Reuters that it expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year.
Cipla, India's third-largest drugmaker by sales, has an existing partnership with Lilly to sell and promote the latter's diabetes drugs in India.
"We've now got a very nice relationship with Lilly over the insulin range we sell for them," Vohra said, adding that the company is prepping for new launches in the U.S., India and South Africa this year.
Meanwhile, Cipla's fourth-quarter revenue of 61.63 billion rupees ($738.4 million) missed analysts' expectations of 62.41 billion rupees, per LSEG, sending its shares down as much as 3.1 per cent. They trimmed some losses and were last down 1.6 per cent.
"Revenue was below consensus mainly due to weakness in India consumer business," said Shrikant Akolkar, an analyst Nuvama Institutional Equities.
The company reported a 78.5 per cent increase in net profit to 9.39 billion rupees, above analysts' estimate of 8.11 billion rupees.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd